🇯🇵·1d agoIndustry
Roche Announces Phase III CELESTIMO Study Results for Lunsumio in Relapsed or Refractory Follicular Lymphoma
Publisher
C
Chugai Pharmaceutical
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- September 17, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/23h ago
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Interpharma Switzerland/1d ago
Was einen starken Forschungsstandort ausmacht
Chugai Pharmaceutical News/1d ago
ルンスミオに関するロシュ社の発表について（再発又は難治性濾胞性リンパ腫に対する国際共同第III相CELESTIMO試験のデータ）
Roche Newsroom/1d ago